Advice
Following an abbreviated submission:
granisetron 3.1mg / 24 hours transdermal patch (Sancuso®) is accepted for use within NHS Scotland.
Indication under review: in adults for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.
Granisetron 3.1mg / 24 hours transdermal patch is slightly more expensive than the oral formulation. It provides an alternative option in patients who have difficulty swallowing oral medication.
Download detailed advice90KB (PDF)
Medicine details
- Medicine name:
- granisetron (Sancuso)
- SMC ID:
- 895/13
- Indication:
- Indicated in adults for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.
- Pharmaceutical company
- ProStrakan
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 October 2013